Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use RotaTeq safely and effectively. See full prescribing information for RotaTeq. RotaTeq® (Rotavirus Vaccine, Live, Oral, Pentavalent) Oral SolutionInitial U.S. Approval: 2006
Medication labelWhy this: Advisory · dailymed-other
RotaTeq® is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age [see Dosage and Administration (2)].
- generic_name
- rotavirus vaccine, live, oral, pentavalent
- product_names
- Rotavirus Vaccine, Live, Oral, Pentavalent
- ndc
- 0006-4047, 0006-4047-01, 0006-4047-02, 0006-4047-41, 0006-4047-20
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en